Results 151 to 160 of about 17,446 (256)
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi +19 morewiley +1 more sourceTumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma
Molecular Oncology, EarlyView.Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt +10 morewiley +1 more sourceABSTRACTS
Wildlife Biology, 1991 J. G. Morgan, H. A. Pereira, T. Sukiennicki, J. K. Spitznagel, J. W. Larrick, D. R. Forsdyke, S. Blum, D. P. Sideris, R. E. Forsdyke, H. Yu, E. Carstens, T. Hattori, Y. Yamamura, Y. Ohmoto, T. Nishida, K. Takatsuki, P. Tekamp-Olson, C. Gallegos, D. Bauer, J. McClain, B. Sherry, M. Fabre, S. van Deventer, A. Cerami, M. Napolitano, W. S. Modi, V. H. Seuanez, S. J. Cevario, W. J. Leonard, T. Schall, K. Toy, D. V. Goeddel, C. A. Hébert, F. W. Luscinskas, J-M. Kiely, E. A. Luis, W. C. Darbonne, G. T. Bennett, C. C. Liu, M. S. Obin, M. A. Gimbrone, J. B. Baker, K. A. Brown, F. Le Roy, G. Noble, K. Bacon, R. Camp, A. Vora, D. C. Dumonde, P. D. Collins, P. J. Jose, T. J. Williams, M. Rampart, J. Van Damme, W. Fiers, A. G. Herman, O. Pos, M. F. Geertsma, A. Stevenhagen, P. N. Nibbering, R. van Furth, K. B. Bacon, R. D. R. Camp, A. B. Millar, A. Meager, S. J. G. Semple, G. A. W. Rook, M. Stein, S. Gordon, K. Morrison, D. B. Jones, E. Y. Jones, D. I. Stuart, N. P. C. Walker, M. K. Thomsen, C. G. Larsen, K. Thestrup-Pedersen, M. Kristensen, K. Paludan, B. Deleuren, K. Kragballe, K. Matsushima, J. M. Wang, G. Taraboletti, A. Mantovani, A. Sica, K. Zachariae, I. Colditz, M. Baggiolini, F. Q. Cunha, B. B. Lorenzetti, S. H. Ferreira, T. J. Standiford, S. L. Kunkel, R. M. Strieter, S. W. Chensue, J. Westwick, K. Kasahara, R. A. Ribeiro, L. H. Faccioli, G. E. P. Souza, C. A. Flores, K. Kasahara, D. G. Quinn, A. Haslberger, C. Foster, M. Ceska, N. Ryder, E. Kugler, I. Lindley, J. N. W. N. Barker, M. L. Jones, R. S. Mitra, C. Swenson, K. Johnson, J. C. Fantone, V. M. Dixit, B. J. Nickoloff, C. Lam, L. Klein, A. Tuschil, J. Y. Shyy, Y. S. Li, D. W. Massop, J. F. Cornhill, P. E. Kolattukudy, R. Pleass, Z. Brown, L. Fairbanks, R. Thomas +129 moreopenaire +1 more sourcePAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model
Molecular Oncology, EarlyView.Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann +10 morewiley +1 more source
